Table 1. Patients and tumor characteristics in the primary and salvage LT groups.

	Types of LT			Types of donor in salvage LT
	Primary LT	Salvage LT	P	DDLT	LDLT	P
	N = 180	N = 39	Value	N = 30	N = 9	Value
Gender M/F	162/18	36/3	0.89	28/2	8/1	0.56
Recipient Age	47(26–64)	44(32–65)	0.46	45(32–64)	40(32–57)	0.16
Etiology			0.66			0.56
HBV	172	36		28	8
Other	8	3		2	1
Child-Pugh score (A vs. B and C)	36/142	20/19	0.000	16/14	4/5	0.93
MELD score	14.2±5.0	11.0±7.4	0.003	11.5±8.1	9.1±3.6	0.40
Pretransplant treatment			0.97			0.93
TACE	60	10		7	3
RFA	15	3		2	1
TACE+RFA	30	5		3	2
All treatments	105(58.33%)	18(46.15%)	0.17	12	6	0.31
Transplant type			0.91			–
LDLT	40	9		–	–
DDLT	140	30		–	–
Serum AFP level, ng/mL			0.02			0.42
≤400	92	28		23	5
>400	88	11		7	4
Tumor size (cm)			0.42			0.87
≤5	122	29		23	6
>5	58	10		7	3
Tumor number			0.68			0.23
Single	108	22		19	3
Multiple (2–3)	72	17		11	6
Microscopic vascular invasion			0.01			0.93
Yes	54	20		16	4
No	126	19		14	5
Differentiation			0.08			0.44
Well (n)	42	10		9	1
Moderate (n)	120	20		14	6
Poor (n)	18	9		7	2
Milan criteria			0.08			0.93
Within criteria	122	20		16	4
Beyond criteria	58	19		14	5
Satellitosis	50 (27.8%)	9 (23%)	0.55	6 (20%)	3 (33%)	0.70
Follow-up, median with range, (mo)	33 (1–133)	30 (1–82)		34 (1–82)	30 (1–80)

Abbreviation: M/F, male/female; HBV, hepatitis B virus; AFP, α fetoprotein; TACE, transarterial chemoembolization; RFA, radiofrequency ablation; LT, liver transplantation; LDLT, living donor liver transplantation; DDLT, deceased donor liver transplantation.